￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

medicaldrugs

Description of the launch time and approval progress of Ritlecitinib in China

2026-02-01 22:25:32

Check Details
Can sparsentan treat primary IgA nephropathy and its efficacy evaluation

2026-02-01 22:25:32

Check Details
Ixazomib price after medical insurance reimbursement and patient actual payment reference

2026-02-01 22:25:32

Check Details
Clinical therapeutic effects of rubitin/rubicatin (Zanbiga) and patient efficacy feedback

2026-02-01 22:25:32

Check Details
Detailed analysis of the adverse reactions and treatment methods of Pimitespib

2026-02-01 22:25:32

Check Details
Whether afatinib maleate tablets (Afatinib) is a targeted drug and its applicable analysis

2026-02-01 22:25:32

Check Details
Dosage specifications and description of applicable patient groups of DaliRasen (Keweike)

2026-02-01 22:25:32

Check Details
Analysis of survival period and efficacy of long-term use of Lynparza

2026-02-01 22:25:32

Check Details
Is the efficacy of venetoclax/venetoclax (venetoclax) reliable and its clinical evaluation analysis

2026-02-01 22:25:32

Check Details
Which country is Asciminib developed in and its R&D background is introduced?

2026-02-01 22:25:32

Check Details
What kind of drugs does ritexitinib (Lefenox) belong to and its pharmacological mechanism analysis

2026-02-01 22:25:32

Check Details
Whether sparsentan (sparsentan) needs to be taken with food and what precautions should be taken

2026-02-01 22:25:32

Check Details
Category
相关知识